Table 2.
Patient characteristics—concomitant medication.
| COVneg (n = 37) | COVpos (n = 50) | Mann–Whitney U or Chi-squared test | |
|---|---|---|---|
| Acetylsalicylic acid (% per group) | 32.4% | 36% | 0.821 |
| Clopidogrel (% per group) | 0% | 4% | 0.505 |
| Prophylactic anticoagulation (% per group) | 56.8% | 24% | 0.003 |
| Intermediate dose anticoagulation (% per group) | 8.1% | 32% | 0.009 |
| Therapeutic dose anticoagulation (% per group) | 35.1% | 44% | 0.51 |
| Statins (% per group) | 24.3% | 24% | 1 |
| ACE blocker (% per group) | 35.1% | 24% | 0.339 |
| Angiotensin II receptor blocker (% per group) | 16.2% | 22% | 0.591 |
| Beta blocker (% per group) | 46% | 28% | 0.113 |
| Aldosterone antagonist (% per group) | 13.5% | 6% | 0.277 |
| Diuretics (% per group) | 50% | 38% | 0.383 |
| Oral glucocorticoids (% per group) | 19% | 56% | 0.001 |
| Remdesivir (% per group) | 0% | 2% | 1 |
| Tocilizumab (% per group) | 0% | 2% | 1 |
| Inhalative bronchodilators (% per group) | 59.5% | 84% | 0.014 |
Data about concomitant medication of COVpos and COVneg in absolute numbers are shown.